1,101 posts by 291 firms and lawyers
Cannabis law explained by the lawyers who practise it: analysis and commentary from law firms around the world, with the Cannabis Law Journal.
Every good legal thriller needs a twist, and this one’s a doozy: The DEA — the agency that’s spent over 50 years playing prohibition’s final boss — is now the one arguing marijuana doesn’t belong in Schedule I anymore, while the…
Brazil’s food and drug regulatory agency Anvisa has initiated administrative proceedings to review advertising regulations for medicines and food products, responding to constitutional challenges…
Cannabis law has never been more contradictory. , federal and state governments often regulate identical products under completely different legal frameworks. Hemp and marijuana can produce the same intoxicating effects, yet…
Thailand’s cannabis regulatory framework continues to move away from the broad commercial liberalization that followed decriminalization in 2022. The latest regulatory developments do not amount to a full recriminalization of…
One of the most frequently cited reasons for slow cannabis reform in many jurisdictions is the obligation to comply with international drug control treaties, particularly the United Nations Single Convention on Narcotic Drugs.
After years of delays and political wrangling, the federal government’s long-awaited hearing on whether to move marijuana from Schedule I to Schedule III of the Controlled Substances Act is finally underway. On Jun. 29th, the DEA…
The Drug Enforcement Administration is scheduled to hold a historic hearing beginning Monday, June 29, 2026, which could extend Schedule III cannabis rescheduling to adult-use marijuana and reshape the federal regulatory…
On April 28, 2026, Acting Attorney General Blanche (“AG”) issued a notice of hearing concerning the proposed rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”).
Article by: Ivy Perez-Bader, Raza Lawrence, Jana Weltzin, Greg Cowan, and Tom Zuber
President Trump has announced he will nominate Todd Blanche — his former personal attorney, who has been running the Department of Justice in an acting capacity — to serve as permanent attorney general.
On April 23, 2026, the Department of Justice and the Drug Enforcement Administration issued an order placing FDA-approved marijuana products and marijuana products subject to a qualifying state-issued medical license in Schedule…
4mg Total THC limit that goes into effect this November has been the focus of much discussion in recent months but perhaps less discussed are the “industrial hemp” carveouts from that limit, and they may be broader than you…
Today, April 23, 2026, the United States Acting Attorney General, Todd Blanche, (the “AG”) and the U.S. Department of Justice (“DOJ”) announced the issuance of a final order that “immediately places” some cannabis into Schedule…
S. S. Food and Drug Administration (FDA)-approved products containing marijuana and marijuana products regulated by a state medical marijuana license in Schedule III of the Controlled Substances Act (CSA).
by mariana.cuzziol, Viviane Kunisawa | Feb 4, 2026 | Cannabis, Client Alert
On December 18, 2025, President Trump signed an Executive Order (the “EO”) directing the Department of Justice (DOJ) to complete the rulemaking process related to rescheduling marijuana to Schedule III and committing to working…
Federal cannabis policy is entering a new phase. The Trump administration’s executive order to reclassify marijuana under the Controlled Substances Act (CSA) marks a historic shift with broad implications for compliance,…
The recent federal policy shift, marked by Executive Order 14370: Increasing Medical Marijuana and Cannabidiol Research, reflects not only a legal development but also a broader cultural transformation.
Brett R. Friedman, Joshua Oyster, David Peloquin, Emily Fruchterman
January 12, 2026 By Edo Banach , Eli Greenspan , Matthew Piscitelli